{"schema_version":"1","generated_at":"2026-11-21T22:23:27.525Z","data_as_of":null,"url":"https://www.findmykol.com/kol/william-tester","json_url":"https://www.findmykol.com/kol/william-tester/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"william-tester","name":"William Tester","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Thomas Jefferson University","institution_url":"https://www.findmykol.com/institution/thomas-jefferson-university","city":"Philadelphia","state":"PA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"William Tester is an Oncology physician affiliated with Thomas Jefferson University. OpenAlex indexes 102 publications with 4,142 citations (h-index 27).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":102,"cited_by_count":4142,"h_index":27,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":13,"shown":3,"withheld":10,"rows":[{"payer":"Exelixis","program_year":2025,"amount_usd":30424,"payment_count":7},{"payer":"Merck & Co.","program_year":2025,"amount_usd":22150.54,"payment_count":1},{"payer":"Exelixis","program_year":2024,"amount_usd":162966.2,"payment_count":18}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":55.8,"classes_total":3,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":26.9,"drugs":[{"name":"Tagrisso","share_pct":49.5},{"name":"Cabometyx","share_pct":14.4},{"name":"Inlyta","share_pct":12.6},{"name":"Mekinist","share_pct":11.7},{"name":"Tafinlar","share_pct":11.7}],"max_beneficiaries":null},{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":22.3,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":29.1,"classes_total":3,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":22.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":20},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":3.9,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":11}]},{"area":"Nervous system","share_pct":7.8,"classes_total":2,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":3.9,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":3.9,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":12}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":11.3,"facility_pct":88.7},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.5_suppl.815","status":"verified"},{"title":"T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer","year":2024,"journal":"Cancer Biology & Therapy","source_url":"https://doi.org/10.1080/15384047.2024.2356820","status":"verified"},{"title":"Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.02082","status":"verified"},{"title":"Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma","year":2024,"journal":"Molecules","source_url":"https://doi.org/10.3390/molecules29081896","status":"verified"},{"title":"Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy","year":2022,"journal":"JAMA Network Open","source_url":"https://doi.org/10.1001/jamanetworkopen.2022.42378","status":"verified"}],"source":"works"},"similar":[{"name":"Vincenzo Berghella","slug":"vincenzo-berghella","institution":"Thomas Jefferson University","specialty":"Maternal & Fetal Medicine","url":"https://www.findmykol.com/kol/vincenzo-berghella","json_url":"https://www.findmykol.com/kol/vincenzo-berghella/profile.json"},{"name":"Bonita Falkner","slug":"bonita-falkner","institution":"Thomas Jefferson University","specialty":"Nephrology","url":"https://www.findmykol.com/kol/bonita-falkner","json_url":"https://www.findmykol.com/kol/bonita-falkner/profile.json"},{"name":"David Whellan","slug":"david-whellan","institution":"Thomas Jefferson University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/david-whellan","json_url":"https://www.findmykol.com/kol/david-whellan/profile.json"},{"name":"Howard Eisen","slug":"howard-eisen","institution":"Thomas Jefferson University","specialty":"Advanced Heart Failure and Transplant Cardiology","url":"https://www.findmykol.com/kol/howard-eisen","json_url":"https://www.findmykol.com/kol/howard-eisen/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":10,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}